{"id":"W4417526956","doi":"10.1016/j.cllc.2025.12.005","title":"Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Chemotherapy; Lung cancer; Osimertinib; Phases of clinical research; Pemetrexed; Disease; Adenocarcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002400516,0.001038922,0.002011347,0.0002752652,0.0003247766,0.001095068,0.0006167767,0.001117447,0.003296799],"category_scores_gemma":[0.002871845,0.0002566952,0.003741165,0.0004479882,0.0005432382,0.0009640285,0.0004864564,0.003094672,0.0003972156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008660916,"about_ca_system_score_gemma":0.0008190805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001125247,"about_ca_topic_score_gemma":0.002921431,"domain_scores_codex":[0.9990306,0.0005193343,0.00005762644,0.0001556606,0.00008215904,0.00015457],"domain_scores_gemma":[0.9983431,0.0005812111,0.0004696783,0.0001181141,0.0000790798,0.0004088969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9286961,0.002619216,0.01700578,0.0007041062,0.007397035,0.0001510614,0.00008252937,0.003289734,0.00274951,0.0002817807,0.004995085,0.0320281],"study_design_scores_gemma":[0.5481058,0.1785369,0.2318619,0.000371616,0.02020217,0.0007461524,0.0002805442,0.005712934,0.002954176,0.002252446,0.008815196,0.0001601395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987493,0.005042742,0.0002314523,0.0007439631,0.0001896701,0.0002378865,0.003987702,0.00002622386,0.002047344],"genre_scores_gemma":[0.9895855,0.001380356,0.0002420467,0.0006851204,0.0002497116,0.0002591489,0.006314044,0.00001848544,0.001265628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003296799,"threshold_uncertainty_score":0.01269531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02508663360335096,"score_gpt":0.4423766151278952,"score_spread":0.4172899815245443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}